Alexandre Le Vert, CEO and Co-Founder of Osivax, explores some evolving approaches to vaccine development that aim to counter the effects of virus mutation.
The COVID-19 pandemic has demonstrated the need for an improved vaccine approach to temper the serious threat of constantly mutating viruses, such as influenza and coronaviruses, on global health. Current vaccines often employ a B-cell immune response through the production of specific antibodies that target the virus’ surface, which can be highly prone to mutation. This strategy cannot anticipate virus mutations and leaves individuals vulnerable to infection when new strains emerge. New T cell-based approaches move beyond the surface and can be combined with B-cell vaccines to address the internal, less variable, parts of viruses to provide broad-spectrum protection against current strains and those yet to come.1
Addressing the ever-changing virus
The surface of a virus is covered with exposed proteins or antigens, which enable it to bind to the receptors of a host cell. Once attached, the virus can alter the function of a cell, allowing it to replicate and produce thousands of copies of itself. Eventually, this leads to the breakdown of the cell’s membrane, releasing more viruses into circulation that can proceed to infect nearby cells. Viruses such as influenza or Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2; the cause of COVID-19) typically infect cells located in the respiratory system, causing inflammation of the trachea and/or the lungs.
Figure 1: Internal and external virus structures2
In influenza and SARS-CoV-2, the haemagglutinin and spike surface antigens are capable of spontaneous mutation and thus display several functioning shapes of these antigens, further splitting themselves into various strains or variants. As a virus circulates and infects host cells to replicate and proliferate, this new virus entity could carry a different protein structure than its ancestral virus, leading to the emergence of a new strain. These spontaneous mutation events are quite common and often do not lead to an improved version of the pathogen. However, sometimes, the new variant exhibits advantageous features, such as faster propagation due to an improved affinity of its mutated surface antigens with the host cell receptors.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Alongside improved sanitation and better nutrition, vaccination remains one of the most cost-effective measures to reduce the burden of infectious diseases. Most currently available vaccines are developed to treat viruses by attacking surface antigens. In influenza, the haemagglutinin is targeted using a small dose of the weakened virus to trigger the production of specific antibodies that bind to it, thereby neutralising the virus when a real infection arises. These quadrivalent influenza vaccines (QIV), however, lack the capacity to produce cross-reactive responses that can neutralise multiple influenza strains. Cross-reactivity is a necessary component in targeting the antigenic plasticity of the haemagglutinin. Each year, global vaccine organisations must ‘predict’ the future circulating strain months in advance. If the prediction is incorrect, this could lead to antigenically drifted viruses and potential mismatches with vaccine strains.3 Improved, broad-spectrum vaccines are needed to address the challenges posed by the difficulty and time-sensitivity of making accurate predictions against these highly mutating viruses.
The COVID-19 pandemic has demonstrated the need for an improved vaccine approach to temper the serious threat of constantly mutating viruses”
One approach to achieving this goal is to target the more conserved regions of the virus, such as internal antigens, which are not under selection pressure from the antibody component of the immune system and are therefore far less prone to mutations. Unlike surface antigens that are visible on the membrane of the virus and can be detected by antibodies, internal antigens are inside the virus and can only be detected by the cellular T-cell component of the immune system.
The adaptive immune response to a natural infection
Our immune system creates new cells daily to combat harmful pathogens. When a virus escapes the first line of defence (the innate immune response) and starts replicating widely, the immune system deploys a highly specific adaptive response composed of two arms: antibody responses that can directly neutralise the virus, and cytotoxic T cells that will destroy and clear the cells infected by the virus.
When a cell is infected by a virus, all the proteins produced by the infected cell, including its inner component, are presented on the cell surface. Cytotoxic T cells can recognise those viral proteins and release chemical signals to induce apoptosis, or the death of the infected cell. These cells also produce memory T cells to respond faster and prevent future infections from occurring. Presenting surface antigens of a virus to the immune system to trigger an antibody-based response has been the landmark of vaccine development. It has worked efficiently against the dangerous pathogens that cause measles, rubella and tetanus. However, relying solely on this vaccine strategy to tackle viruses with high mutation rates has its limitations, as mutating surface antigens evolve constantly. Several biotechs in the space have identified that vaccines that combine a T cell-mediated immune response with the antibody response could potentially improve protection in line with the natural function of the immune system.
Improved, broad-spectrum vaccines are needed to address the challenges posed by the difficulty and time-sensitivity of making accurate predictions against these highly mutating viruses”
Both B-cell and T-cell responses are mediated by two different synergistic pathways that can recognise different parts of the virus and attack at different stages of its proliferation. Several approaches are in development, including nanoparticles or messenger RNA (mRNA) vaccines that have been engineered to display multiple regions of the haemagglutinin known to provide better cross-protection across all lineages of a single virus.
Another disruptive approach, explored by private biotech companies such as Osivax or Imutex, consists of vaccines targeting the heart of a virus, rather than its mutating surface, and doing so with the cellular component of the immune system (T cells).
Targeting the heart of the virus with a T-cell approach
Osivax, a French biotech, has developed its proprietary oligoDOM® technology platform to elicit a T-cell immune response targeting the internal antigens of a virus. Its mechanism of action relies on the combination of (i) a cargo effect of nanoparticles presenting seven copies of the targeted antigens and (ii) a targeting and activating sequence towards the immune system’s cellular surfaces. Results demonstrate the oligoDOM® platform’s ability to trigger a universal response capable of protection against all variants of a single virus. In influenza, the company’s lead programme, OVX836, targets the nucleoprotein – an inner and conserved antigen, which has more than 90 percent genetic similarity among A-strains of the influenza virus.
Figure 2: Osivax’ innovative oligoDOM® technology, an improved self-assembling nanoparticle approach, targeting internal and invariant parts of viruses2
In pre-clinical models, this approach demonstrated cross-protection against all A and B strains tested. In Osivax’ Phase IIa clinical trial in 300 healthy volunteers, OVX836 demonstrated an excellent safety profile, a robust and dose-dependent activation of the cellular component of the immune system, and a strong signal of protection against influenza symptoms.4 An additional Phase II clinical trial is planned to evaluate the co-administration of OVX836 with a standard QIV, empowering a double-punch approach to tackle the virus. Simultaneously, Osivax is advancing another broad-spectrum pre-clinical vaccine candidate against coronaviruses, which targets the nucleocapsid – an internal antigen of the SARS-COV-2 virus.
Conserved antigens, such as the nucleoprotein in influenza and the nucleocapsid in SARS-COV-2, have been recognised as significant targets for T cell-based broad-spectrum vaccine development. Combining a T-cell and B-cell response to tackle highly mutating viruses appears to be a promising means of providing enhanced efficacy in protection and cross-reactivity against all strains of a virus.
Broad-spectrum vaccines could provide robust protection against potential future outbreaks and/or pandemics of highly mutating viruses. While the emergence of COVID-19 certainly demonstrated the need for improved approaches to immunisation, it also showcased that progress in this area can be made rapidly when innovators work together.5 The vaccinology space remains one to watch as companies continue developing next-generation technologies, such as those focused on T-cell responses, intending to provide protection against viruses currently in circulation and those that are yet to come.
About the author
Alexandre Le Vert is the Chief Executive Officer and Co-Founder of Osivax. He has more than 20 years of experience in healthcare, ranging from research and development to commercialisation of vaccines and therapeutics. He is an experienced entrepreneur in biotech and innovation and currently serves as a Board Member of several biotech companies in France and the US. Alexandre is a graduate of EcolePolytechnique and Harvard University.
Madsen A, Cox R. Prospects and Challenges in the Development of Universal Influenza Vaccines. Vaccines. 2020;8(3):361.
Leroux-Roels I, Waerlop G, Tourneur J, et al. Randomized, double-blind, reference-controlled, phase 2a study evaluating the immunogenicity and safety of OVX836, a nucleoprotein-based influenza vaccine [Internet]. Frontiers. Frontiers; 1AD [cited 2022Apr26]. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.852904/full
A very well written article on a highly technical subject which even a layman like me can understand. The technical case is clear. But what about matters relating to economics? Is a broad spectrum vaccine affordable without Government subsidy? Would it just be another product for the rich?
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
A very well written article on a highly technical subject which even a layman like me can understand. The technical case is clear. But what about matters relating to economics? Is a broad spectrum vaccine affordable without Government subsidy? Would it just be another product for the rich?